Kyung Nam Pharm to Cancel 3 Billion KRW Convertible Bonds, Boosting Shareholder Value
Kyung Nam Pharm's board resolved to cancel its 7th and 8th series unsecured private convertible bonds totaling 3 billion KRW, scheduled for June 23, 2026.
These bonds were previously acquired by the company in January and February 2025 via call option and negotiation, leaving only 2.5 billion KRW of the 8th series outstanding after cancellation.
The cancellation aims to enhance shareholder value by eliminating dilution factors, and is expected to prevent dilution equivalent to approximately 9.5% of total outstanding shares.
[AI Summary]Kyung Nam Pharm's cancellation of 3 billion KRW in treasury convertible bonds removes potential dilution risk, positively impacting shareholder value. However, the prior cash outlay for repurchase and the remaining 2.5 billion KRW in convertible bonds warrant continued monitoring. This action is likely to support stock price stability and improve investor sentiment.
KOSDAQ Filing Information
Other Management Matters (Voluntary Disclosure) - Decision To Retire Own Debentures (7th And 8th Series Bearer Interest-Bearing Unsecured Private Convertible Bonds)